Metabolic reprogramming in cholangiocarcinoma
Metabolic reprogramming is a hallmark of cancer and allows tumour cells to meet the
increased energy demands required for rapid proliferation, invasion, and metastasis …
increased energy demands required for rapid proliferation, invasion, and metastasis …
REDD1 Is a Promising Therapeutic Target to Combat the Development of Diabetes Complications: A Report on Research Supported by Pathway to Stop Diabetes
S Sunilkumar, MD Dennis - Diabetes, 2024 - diabetesjournals.org
The stress response protein regulated in development and DNA damage response 1
(REDD1) has emerged as a key player in the pathogenesis of diabetes. Diabetes …
(REDD1) has emerged as a key player in the pathogenesis of diabetes. Diabetes …
[HTML][HTML] Fructose stimulated colonic arginine and proline metabolism dysbiosis, altered microbiota and aggravated intestinal barrier dysfunction in DSS-induced colitis …
G Song, Q Gan, W Qi, Y Wang, M Xu, Y Li - Nutrients, 2023 - mdpi.com
The dysbiosis of intestinal microbiota and their metabolites is linked to the occurrence and
development of metabolic syndrome. Although fructose has been proven to be associated …
development of metabolic syndrome. Although fructose has been proven to be associated …
[HTML][HTML] γ-aminobutyric acid B2 receptor: A potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus
C Saengboonmee, S Sorin… - World Journal of …, 2023 - ncbi.nlm.nih.gov
BACKGROUND The association between diabetes mellitus (DM) and the increased risk and
progression of cholangiocarcinoma (CCA) has been reported with unclear underlying …
progression of cholangiocarcinoma (CCA) has been reported with unclear underlying …
High glucose enhances the aggressiveness of lung adenocarcinoma via activating epidermal growth factor receptor/signal transducer and activator of transcription 3 …
S Sorin, Y Zhou, K Thithuan, K Khawkhiaw… - The Journal of …, 2023 - Elsevier
Epidemiological studies revealed hyperglycemia as a poor prognostic factor for lung
adenocarcinoma with unclear molecular mechanisms. The present study thus aimed to …
adenocarcinoma with unclear molecular mechanisms. The present study thus aimed to …
[HTML][HTML] Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo
R Trakoonsenathong, W Kunprom, C Aphivatanasiri… - Scientific Reports, 2024 - nature.com
Glucagon-like peptide 1 receptor (GLP-1R) agonist is an emerging anti-diabetic medication
whose effects on the risk and progression of cholangiocarcinoma (CCA) are controversial …
whose effects on the risk and progression of cholangiocarcinoma (CCA) are controversial …
Hyperglycemia alters O-GlcNAcylation patterns of hepatocytes in mice treated with hepatoxic carcinogen
S Chomphoo, W Kunprom, K Thithuan, S Sorin… - in vivo, 2023 - iv.iiarjournals.org
Abstract Background/Aim: Diabetes mellitus (DM) is an established risk for hepatocellular
carcinoma (HCC), with unclarified mechanisms. This study investigated the effects of …
carcinoma (HCC), with unclarified mechanisms. This study investigated the effects of …
STAT3 promotes migration and invasion of cholangiocarcinoma arising from choledochal cyst by transcriptionally inhibiting miR200c through the c-myb/MEK/ERK …
W Liu, L Fan, B Shao, Y Zhang - Cellular and Molecular Biology, 2023 - cellmolbiol.org
Signal transducer and activator of transcription 3 (STAT3) have been highlighted in cancer
regulation. Its roles in Cholangiocarcinoma (CCA) arising from the choledochal cyst (CC) …
regulation. Its roles in Cholangiocarcinoma (CCA) arising from the choledochal cyst (CC) …
Obesity and cholangiocarcinoma: A review of epidemiological and molecular associations
S Osataphan, T Mahankasuwan… - Journal of Hepato …, 2021 - Wiley Online Library
Cholangiocarcinoma (CCA) is a malignancy of bile duct epithelium, and its incidence is
increasing globally. Numerous factors are reported associated with an increased risk of CCA …
increasing globally. Numerous factors are reported associated with an increased risk of CCA …
[HTML][HTML] Glucagon-like peptide 1 receptor agonist: A potential game changer for cholangiocarcinoma
R Trakoonsenathong, CF Chiu… - World Journal of …, 2024 - ncbi.nlm.nih.gov
Abstract Glucagon-like peptide-1 receptor (GLP-1R) agonist, a subgroup of incretin-based
anti-diabetic therapies, is an emerging medication with benefits in reducing blood glucose …
anti-diabetic therapies, is an emerging medication with benefits in reducing blood glucose …